Summit to Present Additional Data From Phase 2 CoDIFy Trial Showing Ridinilazole’s Statistical Superiority Over Vancomycin in Sustained Clinical Response was Driven by Marked Reduction in Recurrence of C. difficile Infection
29 mars 2016 09h25 HE
|
Summit Therapeutics plc
Data to be Presented at 26th ECCMID Conference, 11 April 2016 OXFORD, United Kingdom, March 29, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and...
Assembly Biosciences to Webcast Upcoming Investor Conferences
19 févr. 2016 07h30 HE
|
Assembly Biosciences, Inc.
INDIANAPOLIS, Feb. 19, 2016 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a public biotechnology company advancing a new class of oral biologic drugs for addressing the gut...
Assembly Biosciences Presents Clinical Data at Drug Formulation & Bioavailability Summit Showing Its Oral Gemicel(TM) Technology Achieves Targeted Delivery to the Lower GI Tract
27 janv. 2016 07h30 HE
|
Assembly Biosciences, Inc.
PHILADELPHIA and INDIANAPOLIS, Jan. 27, 2016 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing treatments for infectious diseases including hepatitis B...
Assembly Biosciences to Present at Jefferies Microbiome Summit
16 déc. 2015 07h30 HE
|
Assembly Biosciences, Inc.
INDIANAPOLIS, Dec. 16, 2015 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing curative treatments for infectious diseases including hepatitis B virus...
C. difficile Infection Increases Hospital Costs by 40 Percent Per Case, Study Finds
10 déc. 2015 09h27 HE
|
Premier, Inc.
Patients with C. diff stay in hospital 55 percent longer and are 77 percent more likely to be readmitted CHARLOTTE, N.C., Dec. 10, 2015 (GLOBE NEWSWIRE) -- Clostridium difficile (C. diff),...
Clinical Study Shows Assembly Biosciences' Oral Gemicel™ Technology Can Achieve Targeted Delivery to the Lower GI Tract for Microbiome and Other Applications
09 déc. 2015 07h00 HE
|
Assembly Biosciences, Inc.
—Assembly is Developing Curative Treatments for HBV, Resistant C. difficile Infections (CDI) and Other Infectious Diseases— —Expects to Initiate Phase lb Trial in 2016 Using Gemicel to Deliver...
Summit Therapeutics Reports Financial Results for the Second Quarter Ended 31 July 2015 and Operational Progress
27 août 2015 07h00 HE
|
Summit Therapeutics plc
OXFORD, United Kingdom, Aug. 27, 2015 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...
Summit Therapeutics to Report Second Quarter 2015 Financial Results on 27 August 2015
24 août 2015 07h00 HE
|
Summit Therapeutics plc
OXFORD, United Kingdom, Aug. 24, 2015 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (Nasdaq:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular...
Summit Therapeutics Reports First Quarter Results for the Three Months Ended 30 April 2015
11 juin 2015 07h00 HE
|
Summit Therapeutics plc
OXFORD, United Kingdom, June 11, 2015 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (Nasdaq:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular...